A randomised, double-blind study comparing the efficacy and safety of 145 mg fenofibrate, 10 mg Ezetimibe and their combination in patients with type IIb dyslipidemia and features of the metabolic syndrome

Trial Profile

A randomised, double-blind study comparing the efficacy and safety of 145 mg fenofibrate, 10 mg Ezetimibe and their combination in patients with type IIb dyslipidemia and features of the metabolic syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2011

At a glance

  • Drugs Fenofibrate (Primary) ; Ezetimibe
  • Indications Dyslipidaemias; Hyperlipidaemia; Lipid metabolism disorders; Metabolic syndrome
  • Focus Therapeutic Use
  • Sponsors Laboratorios Fournier
  • Most Recent Events

    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2004-002408-13).
    • 20 Apr 2010 Actual patient numbers amended from (186) to (181) as reported by ClinicalTrials.gov.
    • 11 May 2007 Status change from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top